Short summary: A post hoc analysis of the CANVAS trial found no clear kidney or cardiovascular advantage for canagliflozin 300 mg over 100 mg in adults with type 2 diabetes and high cardiovascular risk. Both doses were associated with fewer primary kidney events than placebo, but the authors described the findings as hypothesis-generating rather than definitive.
What question did the analysis ask?
Canagliflozin is an SGLT2 inhibitor used in the treatment of type 2 diabetes and for some heart and kidney risk-reduction purposes. The CANVAS program studied canagliflozin in people with type 2 diabetes who had established cardiovascular disease or multiple cardiovascular risk factors.
This newer analysis used participant-level data from the CANVAS randomized trial to ask whether the 300 mg dose produced better kidney or cardiovascular outcomes than the 100 mg dose. The analysis included 4,330 participants. It was a post hoc analysis, meaning the dose comparison was made after the original trial data had been collected rather than being the original primary question of the trial.
What did the researchers compare?
The analysis compared people assigned to canagliflozin 100 mg, canagliflozin 300 mg, and placebo. The main kidney outcome combined doubling of serum creatinine, kidney failure, or death from a kidney cause.
Other outcomes included a cardiovascular composite of nonfatal heart attack, nonfatal stroke, or cardiovascular death; hospitalization for heart failure; all-cause mortality; changes in albuminuria; acute kidney injury; and serious hyperkalaemia.
What happened to kidney outcomes?
There was no statistically significant difference in the primary kidney outcome between the 300 mg and 100 mg doses. The hazard ratio was 0.85, with a 95% confidence interval from 0.38 to 1.89. The confidence interval was wide, and the result does not show that one dose was better than the other.
When each dose was compared with placebo, both were associated with fewer primary kidney events:
- 100 mg versus placebo: hazard ratio 0.49, with a 95% confidence interval from 0.25 to 0.95.
- 300 mg versus placebo: hazard ratio 0.41, with a 95% confidence interval from 0.20 to 0.83.
These placebo comparisons do not prove that 300 mg is better than 100 mg. The direct dose comparison is the relevant comparison for that question, and it did not show a significant difference.
What happened to heart outcomes?
The composite cardiovascular outcome was similar with the two doses. The comparison of 300 mg with 100 mg produced a hazard ratio of 0.89, with a 95% confidence interval from 0.74 to 1.08. The analysis also found no significant difference between doses for hospitalization for heart failure or all-cause mortality.
The study was not designed to prove that increasing the dose protects the heart more. The results suggest that a higher dose should not automatically be assumed to provide extra cardiovascular benefit.
What about safety?
The analysis did not identify additional safety concerns with either dose. Acute kidney injury and serious hyperkalaemia were similar between the 100 mg and 300 mg groups. This finding is reassuring within the limits of the analysis, but it does not mean that side effects or sick-day risks can be ignored.
SGLT2 inhibitors can require specific precautions during illness, dehydration, fasting, surgery, or changes in kidney function. The appropriate dose depends on the person’s treatment goal, kidney function, other medicines, and prescribing information in their country.
Why the study limitations matter
- This was a post hoc analysis, not a new randomized trial designed specifically to compare the two doses.
- The participants had type 2 diabetes and high cardiovascular risk, so the findings may not apply to everyone with diabetes.
- The direct dose comparison had wide confidence intervals, so a clinically meaningful difference cannot be ruled out with certainty.
- The authors described the findings as hypothesis-generating rather than definitive.
- The study does not establish which dose is best for an individual person or whether a dose should be increased.
What this may mean for people with diabetes
The analysis suggests that the 100 mg dose may provide substantial kidney and cardiovascular protection in people who are appropriate candidates for canagliflozin, without clear evidence that 300 mg adds more protection. It does not replace guideline-based care or a clinician’s assessment of kidney function, blood glucose, cardiovascular risk, and side-effect risk.
A dose decision may depend on the reason the medicine is being used, current kidney function, other glucose-lowering treatments, blood pressure, hydration, and the person’s ability to follow sick-day instructions. A news article cannot determine the right dose for one patient.
Questions to ask your care team
- What is the main reason I am taking canagliflozin: glucose control, kidney protection, heart-failure risk, or cardiovascular risk?
- Which dose is appropriate for my current kidney function and treatment goals?
- What should I do if I am vomiting, dehydrated, fasting, having surgery, or seriously unwell?
- How should my kidney function, hydration, blood pressure, and glucose be monitored?
- Could any of my other medicines change the benefits or risks of this treatment?
Do not start, stop, or change diabetes medicine because of a news article. Discuss dose and sick-day decisions with the clinician who knows your medical history, kidney function, cardiovascular risk, and current medicines.
Bottom line
In a post hoc CANVAS analysis, canagliflozin 300 mg did not show a significant kidney or cardiovascular advantage over 100 mg. Both doses were associated with fewer primary kidney events than placebo, but the findings are hypothesis-generating and should not be used to change a person’s dose without clinical advice.
Source and evidence summary
- Primary study: Elenjickal and colleagues, a post hoc analysis of the CANVAS randomized trial. Open full text in PMC.
- PubMed record: PMID 42219264.
- Journal DOI: 10.1111/dom.70886.